Issue 131

psych symposium

What to expect at PSYCH Symposium: London 2023

PSYCH Symposium: London 2023 is returning on 6 July at the iconic British Museum to explore the latest challenges and opportunities in the field of psychedelic healthcare.

There is currently a desperate need for innovative treatments for mental health care, and increasing clinical research is showing that psychedelic medicines hold promise in this area.

At PSYCH Symposium: London 2023, experts in the field of healthcare, pharma and life sciences will explore the groundbreaking potential of these medicines and discuss cutting-edge psychedelic research that is pushing the boundaries of mental health and addiction care.

The symposium will also be looking at global and European policy developments, funding challenges and patient access.

READ MORE

UK SEES CALL TO REVIEW PSILOCYBIN SCHEDULING

A UK Parliamentary debate saw crossparty calls to conduct an urgent review of the evidence for psilocybin’s current status as a Schedule 1 drug.

Read More

US FEDERAL AGENCY TO FUND PSYCHEDELIC RESEARCH

The National Institute on Drug Abuse will provide US$1.5 million to study psychedelic medicines in treating addiction.

Read More

BUSINESS AND INVESTMENT

The £8 billion psilocybin boom sweeping Britain. Crispin Blunt MP declared that a ‘psychedelic renaissance’ was under way.

The psychedelic mushroom market. Benzinga looks at the growth of legitimate psilocybin harvesting and illegal retail sales.

ARC: An ethical framework for the delivery of psychedelic therapy. Drug Science sets out a framework for the development of psychedelic medicine.

Cybin doses first patient with CYB004. The three-part Phase I clinical trial is studying intravenous DMT in healthy volunteers.

Filament Health imports iboga from Gabon. The import was authorised under the Nagoya Protocol, which ensures the sharing of benefits in an equitable way.

Can psychedelic drugs help relieve mental illness? The Association of American Medical Colleges explores their efficacy.

The psychedelic renaissance is at risk of missing the bigger picture. Post-prohibition, psychedelic medicines will be used outside of psychiatry.

TheraPsil and Lucy Scientific team up to advance psilocybin access. The partnership will enable Lucy Scientific to sell psilocybin products in Canada.

Clearmind not in compliance with the Nasdaq minimum bid price requirement. Listed securities must maintain a minimum bid price of US$1.00 per share.

On Thursday, 6 July, industry leaders will converge at the iconic British Museum for PSYCH Symposium: London 2023.

Secure your ticket for just £329 + VAT.

TICKET REGISTRATION

SCIENCE AND RESEARCH

Iboga: A psychoactive plant with medical potential. Ibogaine, the psychoactive compound in iboga, has shown promise in treating opioid use disorder.

Researchers demand global action on mental health-related deaths. Within the UK, the prevalence of anxiety and depression is high, with millions affected.

REGULATION AND LEGISLATION

An update on regulatory reform. Progress is being made in California, Maine, Massachusetts and North Carolina.

New York senators approve bill to legalise drug consumption sites. The lawmakers have authorised the first state-sanctioned overdose prevention centre.

Veteran faces prison in the US for using DMT. He had been using the psychedelic medicine to treat cluster headaches.

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Partnership with PSYCH provides the opportunity to engage an audience ready to support the development of psychedelic healthcare.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

For more information and to request the PSYCH media kit, please email grace@psych.global.

REQUEST MEDIA KIT

ARTICLES OF INTEREST

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Partnership with PSYCH provides the opportunity to engage an audience ready to support the development of psychedelic healthcare.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

For more information and to request the PSYCH media kit, please email grace@psych.global.

REQUEST MEDIA KIT

A new start after 60: A music executive has found renewed vitality following his first psychedelic experience at 68.

Low self-esteem, body image issues and poor mental health in teens. Imperial College London has explored the relationship between mental health and body mass index.

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Partnership with PSYCH provides the opportunity to engage an audience ready to support the development of psychedelic healthcare.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

For more information and to request the PSYCH media kit, please email grace@psych.global.

REQUEST MEDIA KIT
Partner with us